Guardant, Zephyr AI Partner on Drug Response and Biomarker Discovery

Guardant Health,, a precision oncology leader, and Zephyr AI, an artificial intelligence-driven precision medicine company, have announced a strategic partnership to generate scalable, data-driven insights that accelerate biopharmaceutical innovation. The collaboration combines both companies’ multimodal molecular data and AI/ML technologies to advance novel cancer biomarkers, improve targeted therapy selection, and enhance response monitoring in drug development.

The partnership will integrate with Guardant’s Infinity AI platform, reinforcing both companies’ commitment to using AI and multimodal data to empower oncologists, researchers, and biopharma developers in transforming cancer care.

“Data is key to conquering cancer,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “By combining our molecular data with Zephyr AI’s analytics platform, we’re helping biopharma partners accelerate drug development and deliver better outcomes for patients worldwide.”

By uniting Guardant’s real-world precision oncology data with Zephyr’s proprietary AI technologies, the partnership enables validated predictions of targeted therapy responses and provides biologically interpretable, actionable insights for researchers.

“This collaboration merges unmatched real-world data, advanced diagnostics, and machine learning to create more precise and impactful oncology solutions,” said Allen Chao, CEO of Zephyr AI. “Together, Guardant and Zephyr AI aim to transform cancer treatment and fulfill the promise of personalized medicine.”